Renin Angiotensin System is the most direct, precise, complete, specific and effective approach to antagonize AngII at its receptor site. A relatively new class of compounds known as Ang II receptor antagonists (SARTANs) has been developed for the treatment of hypertension. They exert their action by blocking the binding of Ang II on the AT1 receptor. Based upon the understanding of molecular interaction of Ang II receptor antagonists at the AT1 receptor some of the common structural feature has been identified, such as a heterocyclic (nitrogen atom) ring system, an alkyl side chain and an acidic tetrazole group. Scientist efforts for development of new molecules belong to category non-peptidic Ang II receptor antagonists with different substituted heterocylic such as imidazole (losartan), pyrazole, triazole and benzimidazole. Candesartan and Telmisartan are clinically used AngII antagonist having substituted benzimidazole nucleus with carboxyl function at 7-position and benzimidazole group at 6-position respectively. Present study is for the use of benzimidazole nucleus is potential core for the angiotensin II receptor antagonist developments.
Loading....